ANXA5 and neoplasm: Similar to the experiments utilizing cisplatin chemotherapy, TC-1 tumor-bearing mice treated with doxorubicin and AnxA5-E7 generated strongest E7-specific CD8+ T cell response as well as potent tumor control and prolonged survival as compared to those in other treatment groups (Supplementary Fig. 12).